Search research articles
Contact Us
Filters
Showing results (61-70 of 74) with videos related to
Page
of 8
Sort By:
Antimicrobial Agents and Chemotherapy
|
January 28, 2005
Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1
Salomé Payen, Albert Faye, Alexandra Compagnucci, et al.
European Child & Adolescent Psychiatry
|
September 28, 2021
A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Clinical Therapeutics
|
March 14, 2024
Advanced Model-based Approach to Evaluate Human Plasma, Cerebrospinal Fluid, and Neuronal mTORC1 Activation Biomarkers After NV-5138 Administration in Healthy Volunteers
Azmi Nasser, J Randall Owen, Roberto Gomeni, et al.
Journal of Child and Adolescent Psychopharmacology
|
February 2, 2023
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day
Stephen V Faraone, Ann C Childress, Roberto Gomeni, et al.
Psychiatry Research
|
January 8, 2021
Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
The Journal of Clinical Psychiatry
|
July 20, 2022
Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of Amphetamine Extended-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Andrew J Cutler, Ann C Childress, Antonio Pardo, et al.
British Journal of Clinical Pharmacology
|
May 19, 2022
The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder
Azmi Nasser, Roberto Gomeni, Zhao Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 14, 2011
A pharmacokinetic PET study of NK₁ receptor occupancy
Stefano Zamuner, Eugenii A Rabiner, Sofia A Fernandes, et al.
Psychiatry Research
|
November 14, 2022
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Clinical Pharmacology in Drug Development
|
March 4, 2022
Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone
Itay Perlstein, Avia Merenlender Wagner, Roberto Gomeni, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 74) with videos related to
Sort By:
Page
of 8
Antimicrobial Agents and Chemotherapy
|
January 28, 2005
Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1
Salomé Payen, Albert Faye, Alexandra Compagnucci, et al.
European Child & Adolescent Psychiatry
|
September 28, 2021
A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Clinical Therapeutics
|
March 14, 2024
Advanced Model-based Approach to Evaluate Human Plasma, Cerebrospinal Fluid, and Neuronal mTORC1 Activation Biomarkers After NV-5138 Administration in Healthy Volunteers
Azmi Nasser, J Randall Owen, Roberto Gomeni, et al.
Journal of Child and Adolescent Psychopharmacology
|
February 2, 2023
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day
Stephen V Faraone, Ann C Childress, Roberto Gomeni, et al.
Psychiatry Research
|
January 8, 2021
Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
The Journal of Clinical Psychiatry
|
July 20, 2022
Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of Amphetamine Extended-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Andrew J Cutler, Ann C Childress, Antonio Pardo, et al.
British Journal of Clinical Pharmacology
|
May 19, 2022
The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder
Azmi Nasser, Roberto Gomeni, Zhao Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 14, 2011
A pharmacokinetic PET study of NK₁ receptor occupancy
Stefano Zamuner, Eugenii A Rabiner, Sofia A Fernandes, et al.
Psychiatry Research
|
November 14, 2022
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Clinical Pharmacology in Drug Development
|
March 4, 2022
Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone
Itay Perlstein, Avia Merenlender Wagner, Roberto Gomeni, et al.
Page
of 8